ClinicalTrials.gg
CompletedNCT06454708Updated Jan 28, 2025

Pharmacokinetics, Safety and Tolerability of Clascoterone Cream 1% in Healthy Chinese Adult Subjects

A Phase 1 interventional study of Clascoterone Cream 1% in Acne Vulgaris, sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.

Enrollment
16th of 19
12 · median 50
Started
2024
with 4 others
Phase 1
2 of 19
1 open now
Registered
15th of 19
by date
Lead sponsor
3 of 19
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 16th largest by enrollment, is one of 5 that started in 2024, is one of 2 in phase 1, and was the 15th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About clascoterone

Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing clascoterone in Acne Vulgaris, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the pharmacokinetics (PK) of Clascoterone Cream, 1% after single dose and repeat dose topical administrations in healthy Chinese adult subjects.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese adult subjects, male or female;
  • 18-45 years of age (18 years old and 45 years old are inclusive, on the day of signing the written );
  • Males should be ≥50.0 kg females should be ≥45.0 kg, respectively, and their [BMI = weight (kg)/height2 (m2)] should be within the range of 19.0 to 28.0 kg/m2 (including critical value);
  • Female subjects of or male subjects whose partners are of childbearing potential should agree and be able to use effective from the time of signing the written informed consent to within 3 months after the last dosing (see Appendix 2 for details);
  • Subjects should be able to communicate well with the investigator and complete the study as per the protocol; subjects should be fully informed about the study and sign a written informed consent voluntarily.

Exclusion criteria

Exclusion Criteria:

  • Subject has a previous history of chronic or serious disease;
  • Subject who has undergone major surgical procedure or procedure affecting drug absorption, distribution, metabolism, or excretion within 6 months prior to screening, or plans to undergo surgery during the study;
  • Subject has a history of drug abuse and drug dependence;
  • Subject who has received any medication prior to screening;
  • Subject has previous allergies or has allergic symptoms;
  • Subject has skin damages;
  • Subject who has consumed alcohol regularly;
  • Subject has positive testing result of drug abuse and narcotics screening ;
  • Subject who has consumed excessive of strong tea, coffee, or caffeine-containing beverages;
  • Subject who has been addicted to smoking;
  • Subject who has intake of grapefruit-rich beverages or foods;
  • Subject who has participated in a clinical study with another drug or device and has used the drug or device prior to screening
  • Subject who has donated blood or bled heavily , or received a blood transfusion or used blood products; or who plans to donate blood or blood components;
  • Subject has abnormal physical examination result at screening, or abnormal result of vital signs, or abnormal findings;
  • Subject has abnormal and results of clinical laboratory tests;
  • Subject who is a pregnant or lactation woman or has positive pregnancy test result;
  • Subject who is unable to follow a uniform diet;
  • Subject who has difficulty in collecting blood, has a history of needle and blood fainting or cannot tolerate venipuncture;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Clascoterone Cream 1%

    Drug: Clascoterone Cream 1%

Interventions

  • Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

06

What researchers measure

Primary outcomes

  1. Time to maximum plasma concentration (Tmax)

    Time to maximum plasma concentration

    Time frame: Day 1

  2. Maximum plasma concentration (Cmax)

    Maximum plasma concentration

    Time frame: Day 1

  3. Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration (AUC0-t)

    Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration

    Time frame: Day 1

  4. Time to maximum plasma concentration (Tmax)

    Time to maximum plasma concentration

    Time frame: Day 7

  5. Maximum plasma concentration at steady state (Cmax,ss)

    Maximum plasma concentration at steady state

    Time frame: Day 7

  6. Minimum plasma concentration at steady state (Cmin,ss)

    Minimum plasma concentration at steady state

    Time frame: Day 7

Secondary outcomes

  1. AEs and SAEs

    Incidence and severity of all adverse events (AEs) and serious adverse events (SAEs), and their relevance with the investigational drug.

    Time frame: Day 7

  2. Temperature

    Incidence of abnormal clinically significant temperature results.

    Time frame: Day 7

  3. Pulse rate

    Incidence of abnormal clinically significant pulse rate results.

    Time frame: Day 7

  4. Blood pressure

    Incidence of abnormal clinically significant blood pressure results.

    Time frame: Day 7

07

Study locations

1 site
  • Huashan Hospital, Fudan University
    London, N1 9JP, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2024, 0 months.

Of 44 industry-sponsored phase 1 interventional studies under Acne Vulgaris, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 7. This study's 0 months is below that.

Counting every sponsor, half of 51 studies reached it within 5 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 12, 2024
StartActual
Aug 1, 2024
Primary completionActual
Aug 12, 2024
CompletionActual
Aug 12, 2024
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06454708
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Aug 1, 2024
Primary completion
Aug 12, 2024
Completion
Aug 12, 2024
Last update
Jan 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion